Program Topic

Once-Weekly Zepbound: The First and Only GIP and GLP-1 Receptor Agonist for the Treatment of Obesity*

*For adults with obesity (BMI of ≥30 kg/m²) or with overweight (BMI of ≥27 kg/m²) with at least 1 weight-related comorbidity.¹

Program Description

Learn about once-weekly Zepbound^™ (tirzepatide) injection from an obesity thought leader.¹

In this program, you will hear about the prevalence of obesity, our current understanding of obesity, and some clinical guideline recommendations for obesity treatment. You'll learn about Zepbound—the first and only glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of obesity*—including efficacy and safety data from two clinical trials.¹ Finally, we’ll discuss how to start appropriate patients on once-weekly Zepbound.

Program Objectives

Upon completion of the program, participants will have learned the following about Zepbound:

• Mechanism of action
• Clinical trial data, including efficacy and safety findings
• Dosing and administration information
• How to get appropriate patients started